News

Bart GODDYN speaker at IICJ Conference 2017

Bart GODDYN served as panel moderator and speaker for the fifth International In-House Counsel Journal (IICJ) Conference on 28 March 2017 at the Law Society in London, UK. Senior in-house counsel drawn from all business sectors across Europe and North America attended the conference. The conference provided delegates with an ideal opportunity to discover the strategies and solutions companies are adopting across the full range in-house counsel management issues. Bart…

Read More

GODDYN joined FlandersBio

We have great pleasure in announcing that GODDYN has become part of FlandersBio’s membership list. FlandersBio is the networking organization for the life sciences sector in Flanders, a dynamic non-profit, fee-based organization with currently more than 340 members.

GODDYN assists TiGenix in deal with Takeda

GODDYN assists TiGenix in a licensing transaction with Takeda for TiGenix’s product Cx601. TiGenix NV (Euronext Brussels: TIG) and Takeda Pharmaceutical Company Limited (TSE: 4502) have entered into an exclusive ex-U.S. license, development and commercialization agreement for TiGenix’s product Cx601, a suspension of allogeneic adipose-derived stem cells (eASC) injected intra-lesionally for the treatment of complex perianal fistulas in patients with Crohn’s disease. TiGenix will receive an upfront cash payment of…

Read More

GODDYN advises TiGenix on Sepcell project

GODDYN advises TiGenix on TiGenix’s role as coordinator of the SEPCELL project. TiGenix (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms. TiGenix announced on 2 November 2015 that the SEPCELL project has been awarded a €5.4M grant from the European Commission under Horizon 2020, the European Union’s framework programme for research and innovation, to conduct a clinical Phase Ib/IIa trial…

Read More

GODDYN wins 2015 Global Law Experts Award

GODDYN has great pleasure in announcing that Bart GODDYN, who is the firm’s managing partner, has been chosen as the 2015 winner in the category ‘Transactions Lawyer of the Year in Belgium’ by Global Law Experts (GLE).   The award rewards excellence of GODDYN’s transactional and advisory work in the area of Intellectual Property and R&D.   Over recent months, GLE has conducted its extensive nomination and research process for…

Read More

Release of book on copyright for media professionals

GODDYN has great pleasure in announcing the publication of a book on copyright for media professionals by Wim CRIEL (Roularta Media Group). The book, to which Bart GODDYN has contributed, was released on a press conference today. “It has been an honour, a privilege and a pleasure to have contributed to the writing of Wim’s book. The publication is the result of Wim’s remarkable perseverance to have the complex matter…

Read More

GODDYN advises TiGenix on agreement with Lonza

GODDYN has advised TiGenix (Euronext Brussels: TIG) on an agreement with Lonza for the manufacture of stem cell-based treatment of complex perianal fistulas in Crohn’s disease. TiGenix is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from allogeneic expanded adipose-derived stem cells (eASCs) in inflammatory and autoimmune diseases. Lonza is a global leader in biological and cell therapy manufacturing. TiGenix and Lonza announced today an agreement for…

Read More

GODDYN strengthens its legal work for TiGenix

GODDYN further strengthens its legal work for TiGenix (external link). TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with a commercial product and a strong clinical stage pipeline of adult stem cell programmes. Bart GODDYN (through GODDYN BVBA) will continue to cover a broad range of legal matters relevant to the bio-tech industry with a special focus on transactional and advisory work for TiGenix’s R&D, clinical,…

Read More

Bart GODDYN wins 2014 Corporate Intl Legal Award

GODDYN has great pleasure in announcing that Bart GODDYN, who is the firm’s managing partner, was selected as the 2014 winner of the ‘Transactions Lawyer of the Year in Belgium’ by Corporate Intl Magazine. The award rewards excellence of GODDYN’s transactional and advisory work in the area of Intellectual Property and R&D. The Corporate Intl Legal Awards recognize firms in their chosen specialism and reward excellence not only in expertise…

Read More

Publication on the AstraZeneca case

Bart GODDYN published an article, entitled “The AstraZeneca Competition Case: Patent Strategies Constituting Abuse of Dominance”, in the summer edition of the International In-house Counsel Journal (Vol. 7, No. 28, Summer 2014, 1). In its landmark judgment of 6 December 2012, the Court of Justice of the European Union affirmed that AstraZeneca had abused its dominant position by engaging in certain intellectual property strategies aimed at protecting its product against…

Read More